Michael Bruckman
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$3.7MFederal grants as PI7 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
7 awards · $3.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 1, 2023 | NIH | SBIR Phase II SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia | $994K | Haima Therapeutics, LLC |
| Apr 16, 2020 | NSF | SBIR Phase II SBIR Phase II: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology | $949K | Haima Therapeutics, LLC |
| Apr 16, 2020 | NSF | SBIR Phase II SBIR Phase II: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology | $949K | Haima Therapeutics, LLC |
| Jun 1, 2019 | NIH | SBIR Phase I SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia | $300K | Haima Therapeutics, LLC |
| Sep 4, 2018 | DoD | SBIR Phase I Logistical and Functional Evaluation of SynthoPlateTM (Intravenous Synthetic Platelet) Technology for Pre-Hospital Hemorrhage Control | $100K | Haima Therapeutics, LLC |
| 2018 | NSF | SBIR Phase I SBIR Phase I: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology | $225K | Haima Therapeutics, LLC |
| Dec 18, 2017 | NSF | SBIR Phase I SBIR Phase I: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology | $225K | Haima Therapeutics, LLC |
Peer ranks
Federal funding#469
Awards as PI#280
Patents#505
Companies
- Haima Therapeutics, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.